Performance meets
speed with ELEVECTA™
transient cell line

Now recognized by the FDA for its innovative approach
to AAV manufacturing
Get in touch

Fill out the form to talk to a cell line specialist or to request a quote for ELEVECTA™ transient cell line (includes bonus HyClone™ prime expression medium sample)

ELEVECTA™ cell line portfolio for AAV manufacturing

Beyond supporting your gene therapy processes with our technology and application knowledge, we're passionate about advancing solutions in areas where the status quo isn’t good enough. That's why we're excited to tell you about our ELEVECTA™ cell lines ― a significant advancement in viral vector manufacturing.

The ELEVECTA™ transient cell line, based on HEK293 cells, offers a flexible and efficient solution for producing viral vectors using triple transfection. Designed to minimize development time, it helps you quickly advance your gene therapy candidates to clinical trials.

  • High performance: achieve high titers of infectious virus and high percentage full capsids.
  • Enhanced quality: reduce encapsidated host cell DNA, ensuring higher purity and consistency in your viral vectors.
  • Technical support: leverage our comprehensive suite of process development and regulatory support services, designed to accelerate your journey through clinical trials.
  • Adaptability: access the latest advances in cell line engineering - as your needs evolve, seamlessly transition between each cell line, from transient to stable production, with our ELEVECTA™ cell line portfolio.


FDA Advanced Manufacturing Technology (AMT) designation:
ELEVECTA™ transient cell line has been granted the FDA’s Advanced Manufacturing Technology (AMT) designation, recognizing it as an innovative approach to AAV manufacturing that supports product quality and earlier engagement with regulators.

What this means for you:
    • Reduced encapsidated host cell DNA, aligned with FDA and WHO expectations
    • Earlier, more structured FDA interactions to support CMC readiness
    • Reduced regulatory uncertainty from development through clinical manufacturing


Read the press release


See the data! Learn more about the ELEVECTA™ transient cell line's capabilities for high yield and scalable rAAV production with low encapsidated host cell DNA by downloading our app note.

Ask a question

ELEVECTA™ cell line portfolio for AAV manufacturing

The ELEVECTA™ transient cell line is part of the ELEVECTA™ cell line portfolio, which also includes packaging and producer cell line options. This approach streamlines transition between different cell lines as needs evolve. Interconnected through their common parental cell line, the three cell lines create a complete portfolio, supporting regulatory and quality uniformity.

Request a sample

Praesent lacus arcu, mollis ut volutpat pharetra, vulputate quis massa. Nam interdum fringilla bibendum. Maecenas non odio dui. Suspendisse eros ex, ullamcorper et dui non.

Sed feugiat libero eu turpis tincidunt iaculis. In vel aliquam est, at porta neque. Donec hendrerit ultrices consectetur. Integer feugiat massa quis arcu ullamcorper, tristique facilisis massa feugiat. Phasellus risus mauris, pretium vitae tortor non, tristique fringilla tortor. Aliquam volutpat eros ac risus consectetur, quis gravida erat lobortis. Quisque id rutrum enim, sed fermentum nisl. Nulla volutpat turpis ac ligula venenatis maximus. In non dui ante. Sed ullamcorper quis nisi.

Morbi faucibus sit amet dolor sit amet cursus. Quisque vulputate tellus in magna eleifend, ut luctus orci commodo.

Praesent tellus neque, maximus sit amet mauris in, fermentum pharetra ante. Sed sit amet nibh commodo, fringilla lectus ac, dictum velit. Aliquam cursus feugiat congue. Aenean sit amet enim massa. Praesent mollis sagittis est, ut accumsan eros lobortis id. Maecenas at libero ex. Proin quis est vitae tortor ullamcorper pretium eu non nunc. Quisque at lacus accumsan, finibus sapien ac, viverra ligula. Donec commodo bibendum elit sit amet posuere. Curabitur rutrum pharetra nisl, vitae tincidunt ante consectetur et.

Morbi faucibus sit amet dolor sit amet cursus. Quisque vulputate tellus in magna eleifend, ut luctus orci commodo.

Praesent tellus neque, maximus sit amet mauris in, fermentum pharetra ante. Sed sit amet nibh commodo, fringilla lectus ac, dictum velit. Aliquam cursus feugiat congue. Aenean sit amet enim massa. Praesent mollis sagittis est, ut accumsan eros lobortis id. Maecenas at libero ex. Proin quis est vitae tortor ullamcorper pretium eu non nunc. Quisque at lacus accumsan, finibus sapien ac, viverra ligula. Donec commodo bibendum elit sit amet posuere.

Praesent lacus arcu, mollis ut volutpat pharetra, vulputate quis massa. Nam interdum fringilla bibendum.

Sed feugiat libero eu turpis tincidunt iaculis. In vel aliquam est, at porta neque. Donec hendrerit ultrices consectetur. Integer feugiat massa quis arcu ullamcorper, tristique facilisis massa feugiat. Phasellus risus mauris, pretium vitae tortor non, tristique fringilla tortor. Aliquam volutpat eros ac risus consectetur, quis gravida erat lobortis. Quisque id rutrum enim, sed fermentum nisl. Nulla volutpat turpis ac ligula venenatis maximus. In non dui ante.

Morbi faucibus sit amet dolor sit amet cursus. Quisque vulputate tellus in magna eleifend, ut luctus orci commodo.

Praesent tellus neque, maximus sit amet mauris in, fermentum pharetra ante. Sed sit amet nibh commodo, fringilla lectus ac, dictum velit. Aliquam cursus feugiat congue. Aenean sit amet enim massa. Praesent mollis sagittis est, ut accumsan eros lobortis id. Maecenas at libero ex. Proin quis est vitae tortor ullamcorper pretium eu non nunc. Quisque at lacus accumsan, finibus sapien ac, viverra ligula. Donec commodo bibendum elit sit amet posuere. Curabitur rutrum.

BONUS: HyClone™ prime expression medium

Request a free sample of HyClone™ prime expression medium with your first cell line vial*.

This medium is a powerful tool for producing high levels of adeno-associated virus (AAV) vectors with commonly used HEK293 cell line. It not only supports a high density and cell line viability but also allows for consistent production of various AAV serotypes (2, 5, 8, and 9).

*Limited to one (1) sample request per customer and on first-time purchase with ELEVECTA™ transient cell line. Samples are based on availability and qualification.

I want a sample

Praesent lacus arcu, mollis ut volutpat pharetra, vulputate quis massa. Nam interdum fringilla bibendum. Maecenas non odio dui. Suspendisse eros ex, ullamcorper et dui non.

Sed feugiat libero eu turpis tincidunt iaculis. In vel aliquam est, at porta neque. Donec hendrerit ultrices consectetur. Integer feugiat massa quis arcu ullamcorper, tristique facilisis massa feugiat. Phasellus risus mauris, pretium vitae tortor non, tristique fringilla tortor. Aliquam volutpat eros ac risus consectetur, quis gravida erat lobortis. Quisque id rutrum enim, sed fermentum nisl. Nulla volutpat turpis ac ligula venenatis maximus. In non dui ante. Sed ullamcorper quis nisi.

Morbi faucibus sit amet dolor sit amet cursus. Quisque vulputate tellus in magna eleifend, ut luctus orci commodo.

Praesent tellus neque, maximus sit amet mauris in, fermentum pharetra ante. Sed sit amet nibh commodo, fringilla lectus ac, dictum velit. Aliquam cursus feugiat congue. Aenean sit amet enim massa. Praesent mollis sagittis est, ut accumsan eros lobortis id. Maecenas at libero ex. Proin quis est vitae tortor ullamcorper pretium eu non nunc. Quisque at lacus accumsan, finibus sapien ac, viverra ligula. Donec commodo bibendum elit sit amet posuere. Curabitur rutrum pharetra nisl, vitae tincidunt ante consectetur et.

ELEVECTA™ transient cell line

Preseves flexibility while delivering excellent performance and quality - all aimed at quickly advancing candidates to clinical trials.

  • Excellent performance: Achieve high titers of infectious virus, which you can boost further by using enhancers.
  • Enhanced product quality*: Minimize DNase-resistant host cell DNA inside capsids.
  • Innovative: Access advances in cell line engineering across the entire portfolio to support transition between cell lines.
  • Collaborative: Benefit from a comprehensive suite of regulatory support services.

ELEVECTA™ packaging cell line

Contains all genes except the transgene; allows streamlining the screaning of assets that use the same capsid to target the same tissue type.

  • Streamlined screening: Efficiently screen multiple assets that target the same tissue type.
  • Cost-effective approach: Reduce your plasmid costs with single-plasmid transfection compared with triple transfection.
  • One cell line to clinic: Go to clinic with one cell line and simplify your regulatory asks when you’re targeting the same tissue type across your programs.

ELEVECTA™ producer cell line

Contains all genes to produce AAV; simply induce. The result is a simplified, robust, upstream process that easily scales to treat hundreds of thousands.

  • Simplified manufacturing process: Replace multi-step transfection with one-step induction.
  • Easy scalability: Scale up seamlessly to achieve large quantities of AAV material.
  • Enhanced reproducibility: Produce AAV from a monoclonal cell line, enabling batch-to-batch consistency.
  • Reduced COGS: Skip the need for transfection reagent and any plasmid DNA, which are the most expensive raw materials.